No Data
Medicenna Presents Promising Preclinical Data From Its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting
Medicenna Up 7% As Presents "Compelling Results" From ABILITY-1 Clinical Trial at AACR Meeting
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Medicenna Reports MDNA11's Compelling Anti-Cancer Activity Is Associated With Significant Expansion of 'Stem-Like' Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update
Medicenna Therapeutics up 12% Following Third-Quarter Results
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
